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Shear stressIn this review, we will discuss several well-accepted signaling pathways toward calcium-mediatedmechanisms
of cystic expansion. The second messenger calcium ion has contributed to a vast diversity of signal transduction
pathways. We will dissect calcium signaling as a possible mechanism that contributes to renal cyst formation.
Because cytosolic calciumalso regulates an array of signalingpathways,wewillﬁrst discuss cilia-induced calcium
ﬂuxes, followed byWnt signaling that has attributed tomuch-discussed planar cell polarity.Wewill then look at
the relationship between cytosolic calcium and cAMP as one of the most important aspects of cyst progression.
The signaling of cAMPonMAPK andmTORwill also bediscussed.We infer thatwhile cilia-induced calciumﬂuxes
may be the initial signaling messenger for various cellular pathways, no single signaling mediator or pathway is
implicated exclusively in the progression of the cystic expansion. This article is part of a Special Issue entitled:
Polycystic Kidney Disease.stic Kidney Disease.
artment of Pharmacology, MS
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Polycystic kidney disease (PKD) is characterized by formation of
ﬂuid-ﬁlled cysts. For the past decade, many ideas andmuch hardwork
have been put forth to understand the disease, although the
mechanisms of cyst formation and expansion remain speculations.
Based on transmittance, PKD can be simply classiﬁed into acquired
and hereditary forms. The acquired form of PKD can be found in
patients who have had acute renal failure with subsequent dialysis.
The majority of PKD cases, however, are transmitted hereditarily from
the parents. The two most common hereditary forms of PKD are
autosomal dominant PKD (ADPKD) and autosomal recessive PKD
(ARPKD). The genes mutated in ADPKD include PKD1 and PKD2,
whereas ARPKD is caused by mutation in PKHD1 gene (OMIMs:
#601313, 613095, 263200). The prevalence of ADPKD and ARPKD is 1
in 1000 and 1 in 20,000 live births, respectively.
The products encoded by these PKD genes are called cysto-
proteins (Fig. 1), which include polycystin-1 (PKD1), polycystin-2
(PKD1), and ﬁbrocystin (PKHD1). Though the mechanism of cyst
formation is still a mystery, abnormal function of these proteins
results in cyst formation. In particular, cysto-proteins interact withone another (Fig. 1). Thus, aberrant functions in any of these cysto-
proteins may result in similar pathogenic phenotypes in the kidney,
liver, pancreas and possibly other organs. In addition, these three
proteins are localized within the same subcellular domain in the cell.
Because these proteins are localized and have distinct functions in the
primary cilia, ciliary hypothesis has been developed to explain a
unifying pathogenic concept for PKD.
In this review, we will discuss calcium signaling as a possible
mechanism that contributes to the functions of these cysto-proteins.
Dysfunction of any of these proteins may thus interrupt calcium
signaling pathways, which may promote abnormal downstream sig-
nal transductions of various signaling molecules participating in renal
cyst formation.
2. Calcium signaling by primary cilia
When the PKD genes were discovered and cloned [1–3], their
functions in cation transport immediately became of considerable
interest in understanding themolecular functions of the cysto-proteins.
In particular, sequence analysis of polycystin-2 showed putative
homologies with other known calcium channels [4]. In addition to
their physical and functional interactions with other calcium-regulated
proteins [5–7], interactions of cysto-proteins with other calcium
channels also provided further insights into the modulation of
intracellular calcium signaling [8–12]. Thus, polycystin-2 has long
been predicted to regulate cytosolic calcium [13,14], including modu-
lating intraorganellar calcium release [15] and extracellular calcium
inﬂux [16].
To function as a calcium channel, polycystin-2 depends on its
interaction with polycystin-1 [16,17]. Likewise, proper function of
Fig. 1. Cysto-protein complex. Polycystin-1 and polycystin-2 form a complex with each other at their COOH termini. Functioning as an adaptor protein, Kif bridges the interaction of
between ﬁbrocystin and polycystin complex. Figure is reproduced from Kolb et al. [39] with permission.
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complex [18–20]. In addition, activation of polycystin-2 has been
found to depend on its interaction with mammalian diaphanous-
related forming 1 (mDia1). mDai1 is able to regulate polycystin-2
depending on the membrane potential or voltage levels in the cells.
At resting potentials, mDai1 in an autoinhibited state binds to
polycystin-2 thereby inhibiting its channel activity. However, at
positive potentials, GTP-bound mDia1 releases and thereby allows
activation of polycystin-2 [21].Localization of cysto-proteins to primary cilia further conﬁrms the
roles of polycystins and ﬁbrocystin in intracellular calcium signaling.
In addition, it further elaborates the molecular functions of cysto-
proteins as regulators for intracellular calcium signaling. Most im-
portant are the mechanosensory functions of cysto-proteins that have
been independently described in the mouse and human kidney
epithelia [20,22–27], vascular endothelia [28–30], osteochondrocytes
[31,32], cholangiocytes [33,34] and developing nodes [35–37]. It is
now generally accepted that localization of these cysto-proteins to the
1283S. Abdul-Majeed, S.M. Nauli / Biochimica et Biophysica Acta 1812 (2011) 1281–1290primary cilia is important and necessary to initiate the ﬁrst signaling
cascade of intracellular calcium [38–40]. This signaling pathway may
further provide other complex downstream signaling pathways.
In general, primary cilia are mechanosensory compartments that
house many sensory proteins, including the cysto-proteins. Shear
stress that produces enough drag force on the cell surface is able to
bend the primary cilium (Fig. 2). Subsequently, activation of the
polycystins and other interacting proteins in this complex may result
in cytosolic calcium increase. This paradigm was established based
mainly on in vitro studies where cultured kidney cells were challenged
with a ﬂuid-ﬂow shear stress [41,42]. The ex vivo experiments using
isolated gastrulation stage node, perfused tubules and arteries have
further conﬁrmed the mechanosensory function of the primary cilium
[28,36,43]. In the vascular artery [28], the inﬂux of extracellular
calcium initiates the biochemical cascades that lead to production of
nitric oxide vasodilator through endothelial nitric oxide (eNOS). This
activation of eNOS depends on the contribution or activity of cal-
modulin, phosphoinositide kinase-3, protein kinase B and calcium-
dependent protein kinase (Fig. 3).
In the next sections, we will discuss the downstream pathways
that depend, directly or indirectly, on the initial calcium signaling.
Because of the complexity in calcium signaling, we will discuss only
those pathways that have possible relevance to renal cyst expansion.Fig. 3.Mechanosensory cilia, cytosolic calcium and nitric oxide production. Bending or
activation of the cilia involves mechanosensory polycystin-1 and polycystin-2 complex,
which results in biochemical synthesis of NO. The signaling pathway requires
extracellular calcium inﬂux (Ca2+), followed by activation of various calcium-
dependent proteins including calmodulin (CaM) and protein kinase C (PKC). Together
with PKB, CaM and PKC are important downstream molecular components to activate
endothelial nitric oxide synthase (eNOS).3. Signaling by Wnt
Wnt signaling pathways are involved in many aspects of cell
development, such as cell polarity determination, cell adhesion,
growth, motility, and many others. The Wnt pathway involves a
daunting number of secreted Wnt ligands and Frizzled receptors that
regulate a large number of Wnt signaling molecules. In the simplest
terms, Wnt signaling can activate three distinct pathways (Fig. 4):
(1) β-catenin dependent canonical pathway, (2) β-catenin independent
non-canonical or PCP (planar cell polarity) pathway, and (3) Wnt-
calcium pathway, which can inﬂuence both the canonical and non-
canonical pathways [44].
Many regulatory proteins involved inWnt signaling are localized in
the primary cilium and base of the cilium, also known as basal body. It
is thus speculated that ﬂow-induced cytosolic calcium inﬂux switches
off the canonical Wnt pathway and activates the non-canonical Wnt/
calcium signaling pathway (Fig. 4). This molecular switch is regulated
by inversin, which is a ciliary protein that can turn different Wnt
signaling pathways on and off [45]. Of note is that abnormalities in
inversin function result in polycystic kidney phenotype.
The zebraﬁsh cystic kidney gene seahorse has also been found to be
involved in a variety of cilia-mediated processes such as body
curvature, kidney cyst formation, left-right asymmetry, and othersFig. 2. Primary cilia in signal transduction system. Cilia sense ﬂuid-shear stress on the apical m
will bend sensory cilia. Bending of cilia will activate the cysto-proteins, resulting in extraceincluding PCP signaling and inhibition of the canonical Wnt signaling
[46]. Seahorse seems to be essential for a functional non-canonical
Wnt signaling. It associates with Dishevelled (Dsh), the divergence
point for the canonical Wnt and PCP pathways. The Seahorse gene
encodes a highly conserved ﬁve leucine-rich repeats (LRR) and a
leucine-rich repeat cap, from Drosphila to humans. One of the leucine-
rich repeat proteins, LRRC50, has been found to be conserved in both
zebraﬁsh and humans. Lrrc50 in expressed in all ciliated tissues inembrane of the cells. Fluid ﬂow that produces enough drag-force on the top of the cells
llular calcium inﬂux. Figure is reproduced from AbouAlaiwi et al. [38] with permission.
Fig. 4.Mechanosensory cilia, cytosolic calcium andWnt signaling. Bending or activation of the cilia results inmaintaining cytosolic calcium (Ca2+), followed by activation of inversin.
Calcium and inversin function as the molecular switches for Wnt signaling pathways. The Wnt canonical pathway involves β-catenin. Both β-catenin and E-cadherin regulate cell
differentiation and proliferation. The Wnt non-canonical pathway involves small GTPase rho and JNK, both of which play an important role in planar cell polarity.
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and dog kidney cells, LRRC50 has been shown to localize at themitotic
spindle and cilium, implying it to be a ciliary protein in vertebrates
[47].
It is generally accepted that Wnt signaling pathway is not
regulated properly in polycystic kidney disease (Fig. 4). In the
canonical Wnt pathway, β-catenin in the nucleus mediates many
gene induction events, and any deregulation of this pathway can
result in uninhibited proliferation of cells [48,49]. It is speculated that
ﬂow-induced cytosolic calcium inﬂux is required to turn off the
canonical Wnt pathway and activate the non-canonical Wnt/calcium
signaling pathway. As such, over-activation of canonical Wnt
pathway, by over-production of an activated form of β-catenin for
an example, would result in polycystic kidney phenotype [50]. This
view is consistent with the proﬁling gene expression study [51]. A
consistently high level of Wnt signaling is observed in cystic tissues
from ADPKD patients, but not in tissues which exhibited low level or
no cyst formation from the same patients. Furthermore, abnormalities
in polycystins enhance activity of Wnt signaling pathway [52–55].
E-cadherin is one of the interactingWnt signalingmolecules, and it
plays an essential role in intercellular cell junction assembly. It is
required for epithelial polarity and tubule formation. Disruption of
E-cadherin could lead to abnormal levels of β-catenin and impeding
renal epithelial polarization [54,56]. Furthermore, the protein com-
plex of polycystins, E-cadherin, and β-catenin is interrupted in cyst-
lining epithelial cells in ADPKD patients [57]. In addition, the levels of
β-catenin in the developing hearts and kidneys of Pkd1-/- mouse
embryos compared to wild type embryos is decreased [53]. Overall,the data suggest that interruption in Wnt signaling pathway would
result in less differentiated epithelial cells, yielding to proliferation
and acceleration of cyst expansion [58].
Planar cell polarity, which involves non-canonical Wnt signaling,
has recently been themost discussed topic towards the understanding
of renal cysts. Planar cell polarity is principally involved in the
development of tissue architectures along a parallel axis, other than
the apical–basolateral axis of a renal tubule (Fig. 5). Oriented cell
division is thought to be necessary for the elongation of the developing
nephron. Abnormalities in the planar cell polarity, as reﬂected by the
mitotic spindle, have been observed in various PKD mouse models
[52,59–63]. In these studies, cell division ormitotic spindle orientation
within the tubular axis were measured. However, it is currently
unclear whether such an alignment can be considered a process
toward planar cell polarity [64]. In Drosophila, for example, mitotic
spindle alignment is achieved only after centrosomes have been
properly aligned [65]. Thus, there is a cell-cycle checkpoint for centro-
somal positioning. The question remains whether such a checkpoint is
disrupted in PKD.
Within the non-canonical Wnt signaling, there is also a huge body
of evidence indicating that JNK signaling system is involved in PKD
[66–70]. The strongest evidence of non-canonical Wnt signaling,
however, came from a study involving Rho small G protein. In the
mouse model, mutation in the key regulator of Rho small G protein
results in cystic kidney phenotype [71]. Taken together, interruption
inWnt signaling pathwaywould result in cyst formation due to planar
cell polarity defects, and mitotic spindle orientation might be a
contributing factor in the process.
Fig. 5. Planar cell polarity and cystic kidney disease. The illustration depicts the mechanism of mitotic spindle formation as an index of planar cell polarity in cyst expansion. (a) Each
cilium senses changes in urine ﬂow. This message provides critical calcium signals to the cell. (b) Abnormalities in any of the cysto-proteins results in abnormal ciliary function.
(c) The functional abnormality in ciliary sensing results in disorientation of the mitotic spindle, and hence the cell will lose planar cell polarity. (d) Direction of cell division becomes
randomized. This will result in increasing tubular diameter, rather than tubular elongation. (e) Budding of a cyst from the renal tubule occurs. The abnormal localizations of
epidermal growth factor receptor (EGFR) and Na+/K+ ATPase pump are typical characteristics of polycystic kidneys. (f) The cyst is eventually enlarged and expanded further.
Multiple cysts within a kidney are illustrated on the bottom left corner. Figure is reproduced from Kolb et al. [39] with permission.
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Cyclic adenosine monophosphate, or cAMP, has been identiﬁed as
one of the most important players in cyst progression in both ADPKD
and ARPKD (Fig. 6). Two major processes that contribute to the
expansion of the renal cysts in polycystic kidney disease are cell
proliferation and ﬂuid secretion. cAMP is intimately involved in
accelerating both of these processes [72–75]. Tissues from the kidneys,
liver, and vascular smooth muscles of PKD animal models exhibit
increased levels of cAMP [76–78].
cAMP is known to be one of most important players in effecting
hormonal activation of intracellular pathways and is intimately
involved in cell proliferation in almost all cell lines. However, cAMP
does not produce the same effects in all cell lines. Though cAMP hasbeen used for several years as an anti-proliferative agent [79,80],
cAMP has also been known to stimulate cell proliferation by activating
the mitogen activated protein kinase (MAPK) pathway (Fig. 6). For
example, cAMP is anti-proliferative in normal tissues, but it stimulates
cell proliferation in cystic epithelial cells [73,81,82].
The change in cAMP related phenotype–inhibition of cell prolifera-
tion in normal cells and stimulation of cell proliferation in cystic cells–is
associated with the amount of intracellular calcium in PKD tissues
and cells [82,83]. The imbalance in the cytosolic calcium due to the
disruptions in the cysto-proteins promotes abnormal function of
phosphodiesterase (Fig. 6). Phosphodiesterase 1 isoforms (PDE1a,
PDE1b and PDE1c) are present in especially high levels in the kidneys
[84].Most importantly, theactivity of this phosphodiesterase is regulated
by intracellular calcium and cAMP. In PKD cells with a low level of
Fig. 6. Cytosolic calcium and cAMP signaling. Under normal conditions, the carboxy terminal tails of polycystin-1 and polycystin-2 interact, which enables calcium entry into the cell.
This further stimulates the release of calcium from the calcium stores inside the cell. In the presence of high, steady state levels of calcium, calcium-stimulated phosphodiesterases
are capable of degrading cAMP into AMP, thereby controlling the cAMP levels in the cell. The low levels of cAMP are unable to stimulate MAPK pathway. In polycystic kidneys,
however, the resulting abnormality in cysto-proteins causes a lower level of intracellular calcium. Hence, the activity of phosphodiesterases is not stimulated and cAMP level
increases, leading to activation of B-Raf of MAPK pathway.
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results in aberrant conversion of cAMP to AMP. The resulting increase in
cytosolic cAMP further stimulates the MAPK pathways, which promotes
cyst expansion through higher cell proliferation.
In general, cystic epithelia in polycystic kidneys have exhibited
high levels of both cAMP andMAPK activity compared to normal cells,
resulting in cell proliferation in polycystic kidneys and an inhibition of
cell proliferation in normal cells [85,86]. In normal epithelial cells,
cAMP agonists inhibit MAPK pathway by blocking activation of Raf-1
(Raf-C) through cAMP-dependent protein kinase (PKA). On the other
hand, cAMP was found to stimulate the MAPK pathway in PKD cells,
thereby stimulating cell proliferation. This difference has also been
observed to result from an increased afﬁnity of cAMP for B-Raf rather
than A-Raf and Raf-1 (C-Raf) [82,86]. As mentioned earlier, this
change in cAMP-related signaling is also attributed to the level of
intracellular calcium. The high levels of cAMP, combined with low
levels of calcium ﬂuxes in polycystic kidneys, could further result in a
decrease of PI3K/Akt activity, thereby stimulating B-Raf activation
and hence activation of the MAPK pathway of Ras/B-Raf/MEK/ERK
[83,87,88].
5. Signaling by mTOR
The Ras/Raf/ERK pathway plays another important role in
polycystic kidney disease by regulating the mammalian target ofrapamycin (mTOR) pathway through molecular signaling of tuberin
(Fig. 7). Tuberin, which is also regulated by Akt, is a GTPase activating
protein (GAP). Tuberin regulates the activity of Rheb, a small G-protein
belonging to the Ras super family. GTP-bound Rheb is active, while
GDP-boundRheb is inactive. Hamartin and tuberin formaheterodimer
which converts Rheb-GTP to Rheb-GDP, thereby inactivating Rheb.
Rheb activates mTOR pathway. Hence, tuberin inactivates GTP-bound
Rheb and inhibits the mTOR pathway [89–91].
The respective protein products of TSC1 and TSC2, hamartin and
tuberin, regulate formation of primary cilia [92,93]. Most impor-
tantly, however, analysis of normal and diseased cells from ADPKD
patients indicates that the cyst lining epithelial cells exhibit higher
levels of mTOR signaling compared to the surrounding normal epi-
thelium [94]. When mTOR pathway is inhibited with rapamycin,
many murine models of ADPKD and ARPKD show a decrease in renal
cyst expansion [94–100]. The consensus is that the cytoplasmic tail
of polycystin-1 directly or indirectly interacts with both mTORC1
complex as well as tuberin, the protein product of Tsc2 which itself
regulates mTORC1. Membrane localization of polycystin-1 and ha-
martin are therefore able to bind to tuberin, keeping it near the
plasma membrane. Thus, membrane bound polycystin-1 is capable
of controlling mTORC1 pathway and hence extensive cell prolifera-
tion. Disruption of polycystin-1 would imply the activation of the
mTORC1 cascade yielding cell proliferation and subsequent cyst
formation [101,102].
Fig. 7. Signaling pathway of mTOR. In healthy kidney cells, the cysto-protein complex interacts with tuberin. Hamartin and tuberin form a complex and localize in the basal body.
Tuberin is a GTPase activating protein (GAP) which controls the activity of Rheb. Tuberin inactivates Rheb, thereby inhibiting the mTOR pathway. In polycystic kidneys, however,
tuberin is no longer protected in this complex and is phosphorylated by Akt, RSK (via ERK). As a result, tubulin is unable to form a heteradimer with hamartin. Hence, tuberin is no
longer able inhibit Rheb, and the mTOR pathway is activated.
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activation of the Akt/PKB pathway [101,103,104]. Thus, the inter-
action of Akt and tuberin can further provide an additional regu-
lation of mTOR pathway by the cysto-proteins. Although the role of
calcium in mTOR signaling has still not been properly studied in
polycystic kidney disease, there is a possibility that calcium-ERK-
mTOR pathway could exist. In particular, calcium is known to be
associated with cAMP/ERK activity (Fig. 6), and ERK has been im-
plicated in mTOR signaling (Fig. 7). There is no doubt that further
studies are needed to dissect the contributions of calcium, ERK and
mTOR in cystogenesis.
Interestingly, clinical trials of mTOR inhibitors in ADPKD patients
have not yielded much anticipated results [105–107]. The two mTOR
inhibitors tested in ADPKD patients were sirolimus and everolimus.
Sirolimus was tested on 100 patients (18 to 40 years) exhibiting early
stages of the disease, while everolimus was tried on 433 patients in
advanced-stage II and III, with a renal baseline volume of 1500 mL.
Sirolimus did not show any decrease in total kidney size in humans,
though it showed promising results in mouse models. However, the
animals were treated with a dose of 5 mg/kg of body weight [94], a
dosage that is unsafe for humans, who were administered 2 mg
sirolimus for 18 months. No difference in GFR was observed as these
patients exhibited the initial stages of the disease [105]. Everolimus,
on the other hand, slowed the increase in the total kidney volume
without any effect on GFR. After a brief transient period, patients
exhibited a rapid decline in GFR [106]. These studies imply that
reducing the cyst size need not necessarily improve renal function in
these patients.6. Prospective
Cilia function and structure are important and necessary to
maintain the architecture of kidney tissue. Abnormalities in the
structure or function of cilia results in PKD. The mechanosensory cilia
are crucial in maintaining intracellular calcium signaling. Many cell
types, including renal epithelia, use cytosolic calcium as a second
messenger to further regulate other cellular homeostasis through a
very complex signal transduction system. This signaling system
includes Wnt, cAMP-MAPK, Akt, mTOR, and other pathways that are
not discussed in this review.
In understanding this complexity, an important lesson is that no
single signaling mediator is implicated exclusively in the progression
of the cystic expansion. Rather, all of these signaling pathways are
intimately connected, thereby regulating the progression of the
disease. Nonetheless, only by understanding such a complicated
system do we have better insights to attain the most effective way to
retard progression of polycystic kidney disease.
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